ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1000

Do Preimplantation Biopsies Predict Allograft Loss and Function in Deceased-Donor Kidney Transplants?

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Murthy, Anu, Montefiore Medical Center, New York, New York, United States
  • Nino Torres, Laura, Montefiore Medical Center, New York, New York, United States
  • Dilip, Raga, Montefiore Medical Center, New York, New York, United States
  • Verzani, Zoe, Weill Cornell Medicine, New York, New York, United States
  • Ajaimy, Maria, Montefiore Medical Center, New York, New York, United States
  • Liriano-Ward, Luz E., Montefiore Medical Center, New York, New York, United States
  • Pynadath, Cindy T., Montefiore Medical Center, New York, New York, United States
  • Al Azzi, Yorg, Montefiore Medical Center, New York, New York, United States
  • Jain, Swati, Montefiore Medical Center, New York, New York, United States
  • Yaffe, Hillary C, Montefiore Medical Center, New York, New York, United States
  • von Ahrens, Dagny, Montefiore Medical Center, New York, New York, United States
  • Abdel Muhdi, Nidal, Montefiore Medical Center, New York, New York, United States
  • Le, Marie, Montefiore Medical Center, New York, New York, United States
  • Akalin, Enver, Montefiore Medical Center, New York, New York, United States
Background

Kidney discard rate is up to 29% in the US. Biopsy results are the reason for decline in half of the discarded kidneys. We aim to investigate donor-related factors affecting graft survival, focusing on preimplantation biopsies comparing to clinically indicated biopsies.

Methods

Retrospective analysis of all adult isolated deceased-donor kidney transplant (DDKT) between January 1, 2019 – September 30, 2024, at our center. Donors with > 20% glomerulosclerosis (GS) and > 25% interstitial fibrosis and tubular atrophy (IFTA) or vascular narrowing (VN) were declined.

Results

Of the 796 DDKT, donor median age was 43 (IQR 32-55), 36% were DCD, 32% had final sCr >2 mg/dl, with a median KDPI of 60 (IQR 37,78). Of the 583 patients with preimplantation biopsies, 12% had 10-25% VN, 3.3% had 10-25% IFTA, 9.8% had 10-20% GS. During a median follow up of 24 months (IQR 13,41), 53 patients (6.6%) died and 38 had graft loss (4.7%) and 27 had eGFR<21 ml/min (3.4%). 51% developed DGF. Comparing 38 patients with death-censored graft loss and 27 patients with eGFR < 21 ml/min to surviving patients with eGFR ≥ 21 ml/min, there was a trend but not statistically significant difference in donors with 10-25% VN (p=0.065) and 10-25% IFTA (p=0.078) and 10-20% GS (p=0.4) for graft loss and eGFR < 21ml/min. In multivariate analysis, DCD (HR 1.82, 1.07-3.08 95%CI, p=0.026) and KDPI (HR 1.01, 1.00-1.02 95%CI, p=0.044) were associated with the death-censored graft loss and eGFR < 21 ml/min as donor-related factors. 277 patients underwent graft biopsies at a median of 90 days (IQR 24-201). 58% of the biopsies had a cv score >0 and 20% had ci + ct score >2. When comparing patients with both pre and posttransplant biopsies, only 13% of the posttransplant biopsies with a cv score >0 had VN in the preimplantation biopsy, and none of the posttransplant biopsies with ci+ ct score >2 had pretransplant biopsies documenting 10-25% IFTA.

Conclusion

Preimplantation biopsies did not predict allograft loss and function after KT. A significant number of early clinically indicated biopsies documented increased vascular narrowing require further studies to explore, if it was due to posttransplant injury or poor assessment of preimplantation biopsies.

Digital Object Identifier (DOI)